SlateStone Wealth LLC Acquires Shares of 4,975 ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)

Share on StockTwits

SlateStone Wealth LLC acquired a new stake in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 4,975 shares of the exchange traded fund’s stock, valued at approximately $258,000. SlateStone Wealth LLC owned approximately 0.12% of ProShares Ultra Nasdaq Biotechnology at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Koshinski Asset Management Inc. raised its holdings in shares of ProShares Ultra Nasdaq Biotechnology by 10.7% during the 2nd quarter. Koshinski Asset Management Inc. now owns 5,077 shares of the exchange traded fund’s stock worth $263,000 after buying an additional 490 shares in the last quarter. Capital Investment Advisors LLC raised its holdings in shares of ProShares Ultra Nasdaq Biotechnology by 5.0% during the 2nd quarter. Capital Investment Advisors LLC now owns 9,645 shares of the exchange traded fund’s stock worth $500,000 after buying an additional 455 shares in the last quarter. BNP Paribas Arbitrage SA acquired a new position in shares of ProShares Ultra Nasdaq Biotechnology during the 2nd quarter worth $84,000. Finally, Moors & Cabot Inc. acquired a new position in shares of ProShares Ultra Nasdaq Biotechnology during the 2nd quarter worth $207,000.

Shares of ProShares Ultra Nasdaq Biotechnology stock traded down $1.23 during trading on Thursday, reaching $47.34. 3,924 shares of the company’s stock were exchanged, compared to its average volume of 169,659. ProShares Ultra Nasdaq Biotechnology has a 1-year low of $36.05 and a 1-year high of $70.82. The firm’s 50-day moving average price is $48.57 and its 200 day moving average price is $51.02.

ProShares Ultra Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.

Featured Article: Discount Rate

Want to see what other hedge funds are holding BIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB).

Institutional Ownership by Quarter for ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)

Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Chevron Co.  Shares Sold by Argent Capital Management LLC
Chevron Co. Shares Sold by Argent Capital Management LLC
Argent Capital Management LLC Has $17.43 Million Position in Wells Fargo & Co
Argent Capital Management LLC Has $17.43 Million Position in Wells Fargo & Co
Argent Capital Management LLC Cuts Position in CROWN CASTLE IN/SH SH
Argent Capital Management LLC Cuts Position in CROWN CASTLE IN/SH SH
Mastercard Inc  Stock Holdings Reduced by Argent Capital Management LLC
Mastercard Inc Stock Holdings Reduced by Argent Capital Management LLC
Argent Capital Management LLC Has $68.48 Million Stock Holdings in ConocoPhillips
Argent Capital Management LLC Has $68.48 Million Stock Holdings in ConocoPhillips
Argent Capital Management LLC Makes New $31.06 Million Investment in Centene Corp
Argent Capital Management LLC Makes New $31.06 Million Investment in Centene Corp


 
© 2006-2019 Zolmax.